325 related articles for article (PubMed ID: 20172016)
21. [Experimental study on IL-2- and IL-15 application in allogeneic hematopoietic stem cell transplantation].
Chen GH; Wu DP; Sun AN; Yang MZ; Wang Y; Tang XW; Chang HR; Feng YF; Zhu ZL
Zhonghua Xue Ye Xue Za Zhi; 2008 Aug; 29(8):526-30. PubMed ID: 19112915
[TBL] [Abstract][Full Text] [Related]
22. The effect of human IL-2-activated natural killer and T cells on graft-versus-host disease and graft-versus-leukemia in SCID mice bearing human leukemic cells.
Xun CQ; Thompson JS; Jennings CD; Brown SA
Transplantation; 1995 Oct; 60(8):821-7. PubMed ID: 7482742
[TBL] [Abstract][Full Text] [Related]
23. Reconstitution of natural killer cell receptor repertoires after unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation: analyses of CD94:NKG2A and killer immunoglobulin-like receptor expression and their associations with clinical outcome.
Zhao XY; Huang XJ; Liu KY; Xu LP; Liu DH
Biol Blood Marrow Transplant; 2007 Jun; 13(6):734-44. PubMed ID: 17531784
[TBL] [Abstract][Full Text] [Related]
24. Costimulation of human natural killer cell proliferation: role of accessory cytokines and cell contact-dependent signals.
Robertson MJ; Cameron C; Lazo S; Cochran KJ; Voss SD; Ritz J
Nat Immun; 1996-1997; 15(5):213-26. PubMed ID: 9390270
[TBL] [Abstract][Full Text] [Related]
25. Cytotoxicity of human cord blood natural killer cells is enhanced by recombinant interleukin-15.
Saghafi S; Pourfathollah AA; Kheirandish M; Azimdoust A; Behnia M; Shahjahani M; Moin M
Iran J Allergy Asthma Immunol; 2010 Jun; 9(2):69-77. PubMed ID: 20683100
[TBL] [Abstract][Full Text] [Related]
26. Influence of interleukin IL-2 and IL-12 + IL-18 on surface expression of immunoglobulin-like receptors KIR2DL1, KIR2DL2, and KIR3DL2 in natural killer cells.
Chrul S; Polakowska E; Szadkowska A; Bodalski J
Mediators Inflamm; 2006; 2006(4):46957. PubMed ID: 17047292
[TBL] [Abstract][Full Text] [Related]
27. Abrogation of graft-vs.-leukemia activity after depletion of CD3+ T cells in a murine model of MHC-matched peripheral blood progenitor cell transplantation (PBPCT).
Uharek L; Glass B; Zeis M; Dreger P; Steinmann J; Löffler H; Schmitz N
Exp Hematol; 1998 Feb; 26(2):93-9. PubMed ID: 9472798
[TBL] [Abstract][Full Text] [Related]
28. [The negative regulatory effect of IFN-gamma on cognitive function of human natural killer cells].
Zhang C; Tian ZG; Zhang J; Feng JB; Zhang JH; Xu XQ
Zhonghua Zhong Liu Za Zhi; 2004 Jun; 26(6):324-7. PubMed ID: 15312339
[TBL] [Abstract][Full Text] [Related]
29. Antitumor activity, growth, and phenotype of long-term IL-2 cultures of human NK and T lymphocytes.
Fuchshuber PR; Lotzová E; Pollock RE
Lymphokine Cytokine Res; 1991 Apr; 10(1-2):51-9. PubMed ID: 1651770
[TBL] [Abstract][Full Text] [Related]
30. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
[TBL] [Abstract][Full Text] [Related]
31. Modulation of cell surface markers on NK-like T lymphocytes by using IL-2, IL-7 or IL-12 in vitro stimulation.
Zoll B; Lefterova P; Ebert O; Huhn D; Von Ruecker A; Schmidt-Wolf IG
Cytokine; 2000 Sep; 12(9):1385-90. PubMed ID: 10975999
[TBL] [Abstract][Full Text] [Related]
32. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.
Miller JS; Tessmer-Tuck J; Pierson BA; Weisdorf D; McGlave P; Blazar BR; Katsanis E; Verfaillie C; Lebkowski J; Radford J; Burns LJ
Biol Blood Marrow Transplant; 1997 Apr; 3(1):34-44. PubMed ID: 9209739
[TBL] [Abstract][Full Text] [Related]
33. Endogenous IL-2 production by natural killer cells maintains cytotoxic and proliferative capacity following retroviral-mediated gene transfer.
Miller JS; Tessmer-Tuck J; Blake N; Lund J; Scott A; Blazar BR; Orchard PJ
Exp Hematol; 1997 Oct; 25(11):1140-8. PubMed ID: 9328450
[TBL] [Abstract][Full Text] [Related]
34. IL-7 enhances survival of human CD56bright NK cells.
Michaud A; Dardari R; Charrier E; Cordeiro P; Herblot S; Duval M
J Immunother; 2010 May; 33(4):382-90. PubMed ID: 20386468
[TBL] [Abstract][Full Text] [Related]
35. NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways.
Verhoeven DH; de Hooge AS; Mooiman EC; Santos SJ; ten Dam MM; Gelderblom H; Melief CJ; Hogendoorn PC; Egeler RM; van Tol MJ; Schilham MW; Lankester AC
Mol Immunol; 2008 Sep; 45(15):3917-25. PubMed ID: 18657862
[TBL] [Abstract][Full Text] [Related]
36. Interleukin-10 promotes NK cell killing of autologous macrophages by stimulating expression of NKG2D ligands.
Schulz U; Kreutz M; Multhoff G; Stoelcker B; Köhler M; Andreesen R; Holler E
Scand J Immunol; 2010 Oct; 72(4):319-31. PubMed ID: 20883317
[TBL] [Abstract][Full Text] [Related]
37. Ex vivo expansion of non-MHC-restricted cytotoxic effector cells as adoptive immunotherapy for myeloma.
Wu JY; Ernstoff MS; Hill JM; Cole B; Meehan KR
Cytotherapy; 2006; 8(2):141-8. PubMed ID: 16698687
[TBL] [Abstract][Full Text] [Related]
38. Interleukin-15 supports generation of highly potent clinical-grade natural killer cells in long-term cultures for targeting hematological malignancies.
Suck G; Oei VY; Linn YC; Ho SH; Chu S; Choong A; Niam M; Koh MB
Exp Hematol; 2011 Sep; 39(9):904-14. PubMed ID: 21703984
[TBL] [Abstract][Full Text] [Related]
39. Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy.
Tam YK; Martinson JA; Doligosa K; Klingemann HG
Cytotherapy; 2003; 5(3):259-72. PubMed ID: 12850795
[TBL] [Abstract][Full Text] [Related]
40. Characterization of interleukin-15 gene-modified human natural killer cells: implications for adoptive cellular immunotherapy.
Zhang J; Sun R; Wei H; Zhang J; Tian Z
Haematologica; 2004 Mar; 89(3):338-47. PubMed ID: 15020274
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
